Drug metabolism alterations in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Drug-metabolizing enzymes play a vital role in the elimination of the majority of therapeutic drugs. The major organ involved in drug metabolism is the liver. Chronic liver diseases have been identified as a potential source of significant interindividual variation in metabolism. Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, affecting between 60 and 90 million Americans, yet the vast majority of NAFLD patients are undiagnosed. NAFLD encompasses a spectrum of pathologies, ranging from steatosis to nonalcoholic steatohepatitis and fibrosis. Numerous animal studies have investigated the effects of NAFLD on hepatic gene expression, observing significant alterations in mRNA, protein, and activity levels. Information on the effects of NAFLD in human patients is limited, though several significant investigations have recently been published. Significant alterations in the activity of drug-metabolizing enzymes may affect the clearance of therapeutic drugs, with the potential to result in adverse drug reactions. With the enormous prevalence of NAFLD, it is conceivable that every drug currently on the market is being given to patients with NAFLD. The current review is intended to present the results from both animal models and human patients, summarizing the observed alterations in the expression and activity of the phase I and II drug-metabolizing enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580 · cited 3×
“Both obesity and type 2 diabetes are more prevalent among non-Hispanic black and Mexican-American patients, compared to non-Hispanic whites (Flegal et al., 1998, 2002, 2010; Harris et al., 2002).”
BackgroundFord, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 2×
“Impaired mitochondrial function may lead to activation of lipid catabolic pathways that generate reactive oxygen species, causing lipid peroxidation of the mitochondrial membrane phospholipids, leading to an additional decrease in mitochondrial function and increased oxidative stress in the cell (Browning and Horton,…”
BackgroundBoyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714
Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., & Feldstein, A. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01774.x · Cited by 597
Gene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427 · cited 1×
“Greco et al. (2008) detected CYP1A2 as a significantly decreased gene in microarray studies of NAFLD patients.”
BackgroundFatty liver hepatitis and cirrhosis in obese patients
Adler, M., & Schaffner, F. (1979) · The American Journal of Medicine · doi:10.1016/0002-9343(79)90740-x · Cited by 399 · cited 2×
“Although initially described 30 years ago (Adler and Schaffner, 1979; Ludwig et al., 1980), the true scope of the disease has only recently been understood.”
BackgroundHigh fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo
Mantena, S. K., Vaughn, D. P., Andringa, K. K., Eccleston, H. B., King, A. L., Abrams, G. A., Doeller, J. E., Kraus, D. W., Darley-Usmar, V. M., & Bailey, S. M. (2009) · Biochemical Journal · doi:10.1042/bj20080868 · Cited by 265 · cited 1×
“Relatively few studies reported increases in Cyp2e1; in ob/ob females (but not males), in steatotic mice (but not in NASH mice), in mice fed a high-fat diet, and in mice fed an MCD diet (Ito et al., 2007; Roe et al., 1999; Mantena et al., 2009; Leclercq et al., 2000).”
BackgroundPharmacogenetics of human cytosolic sulfotransferases
Nowell, S., & Falany, C. N. (2006) · Oncogene · doi:10.1038/sj.onc.1209376 · Cited by 158 · cited 1×
“Drugmetabolizing SULTs are cytosolic and belong to SULT1 and SULT2 families (Nowell and Falany, 2006).”
BackgroundDrug-induced liver injury: Is it somehow foreseeable?
Tarantino, G., Minno, M. N. D. D., & Capone, D. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2817 · Cited by 137
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Cobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
Bessone, F., Dirchwolf, M., Rodil, M. A., Razori, M. V., & Roma, M. G. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14952 · Cited by 102
Towards improved hepatocyte cultures: Progress and limitations
Ruoß, M., Vosough, M., Königsrainer, A., Nadalin, S., Wagner, S., Sajadian, S., Huber, D., Heydari, Z., Ehnert, S., Hengstler, J. G., et al. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111188 · Cited by 77
The effects of fasting on drug metabolism
Lammers, L. A., Achterbergh, R., Mathôt, R. A. A., & Romijn, J. A. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1706728 · Cited by 32
“that fasting may contribute to both intra- and inter-individual variations in human drug metabolism as well [21,39].”
Background
Metadata
- Authors
- Merrell, M. D., & Cherrington, N. J.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2011-05-25
- Volume
- 43
- Issue
- 3
- Pages
- 317-334
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2089881587
- Cited by
- 181
- References
- 17
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.